{"entity":{"id":"tango-therapeutics","kind":"company","name":"Tango Therapeutics","aka":[],"tldr":"Tango Therapeutics makes cancer pills that exploit a weakness created when a tumour loses a particular gene. Its lead drug targets cancers that have lost a gene called MTAP, common in pancreatic and lung cancer.","summary":"Tango Therapeutics is a Boston precision oncology company built on synthetic lethality: it uses CRISPR-based functional genomic screens to find targets that cancer cells depend on once they have lost a tumour suppressor gene. Its lead programme, vopimetostat (TNG462), is an MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers, listed in phase 1/2 and phase 3 development in pancreatic, lung and other non-CNS cancers, with a phase 1/2 combination study alongside Revolution Medicines' RAS inhibitors. TNG456, a brain-penetrant PRMT5 inhibitor, is in phase 1/2 for MTAP-deleted glioblastoma. All programmes are wholly owned. Tango listed on Nasdaq in August 2021 through a merger with BCTG Acquisition Corp, a SPAC sponsored by Boxer Capital, with a 186 million US dollar PIPE and about 353 million US dollars in expected total proceeds; Gilead Sciences was an existing shareholder.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.tangotx.com/"},{"label":"Pipeline","url":"https://www.tangotx.com/pipeline/"},{"label":"BCTG merger announcement (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/1819133/000121390021021456/ea139433ex99-1_bctgacq.htm"}],"tags":[],"related":[],"cancers":["pancreatic","nsclc","glioblastoma"],"sections":["targeted-therapy"],"technologies":["synthetic-lethality-approaches","crispr-screens"],"targets":[],"drugs":["tng462","tng456","tng260"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06922591","nct06810544","nct06188702","nct05732831"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year (2017) not sourced from a fetched page. Final proceeds after redemptions were not confirmed; the 353 million figure is the expected total stated in the announcement."],"hq":"Boston, MA","country":"US","companyType":"biotech","website":"https://www.tangotx.com/","ticker":"TNGX","stage":"public","investors":["boxer-capital","bain-capital-life-sciences","ecor1-capital","foresite-capital","logos-capital","ra-capital","samsara-biocapital","casdin-capital","cormorant-asset-management"],"funding":[{"round":"IPO","year":2021,"amountUsd":353000000,"source":"https://www.sec.gov/Archives/edgar/data/1819133/000121390021021456/ea139433ex99-1_bctgacq.htm","note":"Nasdaq listing via merger with BCTG Acquisition Corp; approximately 353 million US dollars expected gross proceeds (about 167 million in trust plus a 186 million PIPE led by Boxer Capital), before redemptions"}]},"route":"/companies/tango-therapeutics/","neighbours":{"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"crispr-screens","kind":"technology","name":"CRISPR functional genomics","route":"/technologies/crispr-screens/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"drug":[{"id":"tng260","kind":"drug","name":"TNG260","route":"/drugs/tng260/"},{"id":"tng456","kind":"drug","name":"TNG456","route":"/drugs/tng456/"},{"id":"tng462","kind":"drug","name":"TNG462","route":"/drugs/tng462/"}],"trial":[{"id":"nct06188702","kind":"trial","name":"S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP","route":"/trials/nct06188702/"},{"id":"nct06810544","kind":"trial","name":"Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss","route":"/trials/nct06810544/"},{"id":"nct05732831","kind":"trial","name":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","route":"/trials/nct05732831/"},{"id":"nct05887492","kind":"trial","name":"Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors","route":"/trials/nct05887492/"},{"id":"nct06922591","kind":"trial","name":"Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients","route":"/trials/nct06922591/"}],"company":[{"id":"bain-capital-life-sciences","kind":"company","name":"Bain Capital Life Sciences","route":"/companies/bain-capital-life-sciences/"},{"id":"boxer-capital","kind":"company","name":"Boxer Capital","route":"/companies/boxer-capital/"},{"id":"casdin-capital","kind":"company","name":"Casdin Capital","route":"/companies/casdin-capital/"},{"id":"cormorant-asset-management","kind":"company","name":"Cormorant Asset Management","route":"/companies/cormorant-asset-management/"},{"id":"ecor1-capital","kind":"company","name":"EcoR1 Capital","route":"/companies/ecor1-capital/"},{"id":"foresite-capital","kind":"company","name":"Foresite Capital","route":"/companies/foresite-capital/"},{"id":"logos-capital","kind":"company","name":"Logos Capital","route":"/companies/logos-capital/"},{"id":"ra-capital","kind":"company","name":"RA Capital Management","route":"/companies/ra-capital/"},{"id":"samsara-biocapital","kind":"company","name":"Samsara BioCapital","route":"/companies/samsara-biocapital/"}]}}